Tracer library / [64Cu]Cu-sartate
[64Cu]Cu-sartate
Also written as Cu-64 SARTATE; SARTATE
- Radionuclide
- Cu-64 t½ 762 min
- Modality
- PET
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 1
What it is
- Compound class
- Sarcophagine-conjugated somatostatin analog peptide (SarTATE, MeCOSar-Tyr3-octreotate)
- Target / mechanism
- Somatostatin receptor (SSTR) binding via octreotate peptide PMID 30442752
- Clinical application
- PET/CT imaging of somatostatin receptor-positive neuroendocrine tumors, with potential for prospective dosimetry for PRRT PMID 30442752
- Theranostic pair
- [67Cu]Cu-SARTATE
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | SarTATE | 42201774 2026 Inorg Chem Copper-64 (46.25 MBq, 1.25 mCi) in 0.1 M HCl was neutralized with PBS and NaOH and combined with SarTATE |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- 64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy.2019 · J Nucl Med · Prospective
- 64Cu Treatment Planning and 67Cu Therapy with Radiolabeled [64Cu/67Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry.2023 · J Nucl Med · Clinical study
Need this precursor?We can point you to suppliers for [64Cu]Cu-sartate, or handle the enquiry for you.
Get in touchQuality control Derived from the published synthesis
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [64Cu]Cu-sartate.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with Cu-64. Also seen with Cu-67[1] (too few articles for own row). Stage set/updated at stage 23 from PMID 30442752: 'we have performed a first-time-in-humans trial of 64Cu-MeCOSar-Tyr3-octreotate (64Cu-SARTATE) to assess its safety and ability to localize disease at early and late imaging time-points'. | Stage 30 (2026-09-18): Stage was 'first-in-human'; normalised to 'Clinical research', original wording kept here.